Scribd
Upload
21 views13 pages

RHF Presentation Final

Rheumatoid Heart Failure (RHF) is a condition affecting rheumatoid arthritis (RA) patients, characterized by increased heart failure risk due to systemic inflammation and immune dysregulation. The incidence of RHF has risen by 15% from 2015-2023, with symptoms including dyspnea, fatigue, and edema, and treatments like methotrexate and TNF inhibitors showing efficacy in reducing heart failure risk. Prognosis indicates a 5-year survival rate of 55%, with ongoing research into AI models and IL-6 blockade for improved management.

Uploaded by

Irrfan jeilan
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
21 views13 pages

RHF Presentation Final

Rheumatoid Heart Failure (RHF) is a condition affecting rheumatoid arthritis (RA) patients, characterized by increased heart failure risk due to systemic inflammation and immune dysregulation. The incidence of RHF has risen by 15% from 2015-2023, with symptoms including dyspnea, fatigue, and edema, and treatments like methotrexate and TNF inhibitors showing efficacy in reducing heart failure risk. Prognosis indicates a 5-year survival rate of 55%, with ongoing research into AI models and IL-6 blockade for improved management.

Uploaded by

Irrfan jeilan
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 13

Rheumatoid Heart Failure (RHF)

An In-depth Analysis of Epidemiology,


Pathophysiology, Symptoms,
Diagnosis, and Treatment
Introduction
• • RHF occurs in RA patients due to systemic
inflammation and immune dysregulation.
• • Unlike traditional heart failure, RHF is
primarily non-ischemic.
• • RA patients have a significantly higher HF
risk compared to the general population.
Epidemiology
• • RA patients have a 2-3x increased risk of HF.
• • Mayo Clinic study: HF risk HR = 1.87.
• • UK Biobank: Women OR = 3.2, Men OR =
1.9.
• • RHF incidence has increased by 15% from
2015-2023 due to better detection.
RHF Incidence Trends
Pathophysiology
• • RHF results from chronic inflammation,
fibrosis, and autoimmunity.
• • TNF-α, IL-6 contribute to myocardial
dysfunction.
• • Myocardial biopsies show a 2.5-3.0 fold
increase in collagen.
• • CMR detects fibrosis in 45-50% of RA
patients.
Pathophysiology of RHF
Symptoms
• • Dyspnea on exertion: 70–80% of patients.
• • Fatigue is prevalent in 90% of cases.
• • Edema affects 50–60% of patients.
• • Reduced exercise tolerance is common.
Diagnosis
• • RA history, symptoms, imaging, and
biomarkers are used.
• • Echocardiography: LVEF ≥50%, E/e’ >14 in
70% of cases.
• • CMR detects fibrosis in 45% asymptomatic
cases.
• • BNP >100 pg/mL is found in 60% of RHF
patients.
Treatment
• • Methotrexate reduces HF risk by 28% (HR
0.72).
• • TNF inhibitors lower HF risk by 20%.
• • SGLT2 inhibitors reduce hospitalizations by
25%.
Treatment Efficacy in RHF
Prognosis & Future Research
• • 5-year survival rate is 55%.
• • AI models predict RHF with 92% accuracy.
• • IL-6 blockade shows promising results for
RHF management.
Emerging Research Timeline for
RHF
Emerging Research Timeline for
RHF

You might also like